Treatment with Monoclonal Antibodies against <i>Clostridium difficile</i> Toxins

Abstract

The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection. (ClinicalTrials.gov number, NCT00350298.)